Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study
AP Mitchell, SB Dusetzina, AM Meza, NU Trivedi… - Bmj, 2023 - bmj.com
Objective To estimate the association between oncologists' receipt of payments from the
pharmaceutical industry and delivery of non-recommended or low value interventions …
pharmaceutical industry and delivery of non-recommended or low value interventions …
Pharmaceutical industry payments to medical oncologists in The Netherlands: Trends and patterns provided by an open-access transparency data set
JB Schnog, MJ Samson, I Gersenbluth… - JCO Oncology …, 2024 - ascopubs.org
PURPOSE Health care expenditure related to oncologic treatments is skyrocketing although
many treatments offer marginal, if any, clinical benefit. Financial conflicts of interest (fCOI) …
many treatments offer marginal, if any, clinical benefit. Financial conflicts of interest (fCOI) …
Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands
AMJ Somers, AJ Duits, MJ Samson, JJB Schnog - Journal of Cancer Policy, 2024 - Elsevier
Background Financial conflicts of interest (FCOI) of medical professionals and associated
organizations with pharmaceutical companies (pharma) might contribute to the use of low …
organizations with pharmaceutical companies (pharma) might contribute to the use of low …
Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study
Objectives To understand how and why Australian cancer physicians interact with the
pharmaceutical industry. Design Qualitative study using semistructured interviews …
pharmaceutical industry. Design Qualitative study using semistructured interviews …